Current funding opportunities related to TB and HIV, expired RFAs will be hidden after closing date. Sort using the tags menu to the right.
For funding opportunities related to global health, please see the Vanderbilt Institute for Global Health announcements found here.
Licensing Opportunity: Improved Antibiotic Therapy of Mycobacterium Tuberculosis
Inhibition of Host Heme Oxygenase-1 as an Adjunctive Treatment to Improve the Outcome of Conventional Antibiotic Chemotherapy of Mycobacterium tuberculosis (Mtb) Infection
This invention describes the adjunctive use of heme oxygenase-1 (HO-1) inhibitors to improve the outcome of conventional antibiotic treatment for tuberculosis. The existent standard of care requires prolonged administration of drug. Due to the long duration of treatment, methods that can more rapidly control tuberculosis in patients are clearly needed.
NIAID researchers have discovered that inhibition of host HO-1 reduces Mycobacterium tuberculosis (Mtb) growth in vivo and, more importantly, when used as an adjunct to conventional chemotherapy, results in a marked improvement in pulmonary bacterial control. In particular, it was found using a mouse model that HO-1 inhibitors enhance bacterial clearance when used in conjunction with conventional antibiotic therapy. Further, no obvious toxic side effects were found. Since this host-directed strategy does not directly target the pathogen itself, it may have an added advantage as a treatment for infections with antibiotic-resistant Mtb strains.
Licensing Contact:
James Robinson,
Email: james.robinson4@nih.gov
Phone: 301-761-7542
More information: https://www.ott.nih.gov/technology/e-174-2016
Myeloid-Derived Suppressor Cells (MDSCs) as Potential Therapeutic Targets in TB/HIV (R01/R21), expires 01/08/2022
Due Dates: January 8, 2020; January 8, 2021; January 10, 2022
The purpose of this Funding Opportunity Announcement (FOA) is to invite applications for support of innovative clinical, preclinical and non-clinical research to determine the potential of MDSCs as a target for host-directed therapeutics for tuberculosis in the context of HIV co-infection, and to better understand the role of host-induced immunosuppression in the progression of Mycobacterium tuberculosis pathogenesis.
R01: https://grants.nih.gov/grants/guide/pa-files/PAR-19-357.html
R21: https://grants.nih.gov/grants/guide/pa-files/par-19-364.html
Doris Duke Charitable Foundation 2019 Clinical Scientist Development Award, due annually in November
Pre-proposals due November 28, 2018
The Clinical Scientist Development Award consists of $150,000 annual direct costs plus $15,000 (10 percent) annual indirect costs for three years. The priority of the CSDA program is to fund outstanding individuals with potential for clinical research careers, whose projects will address highly significant research questions and lead to career advancement. DDCF does not have funding priorities based on disease area or research type.
Vanderbilt-Emory-Cornell-Duke (VECD) Fogarty Global Health Fellowship, due anually in November
Application due: November 1, 2018
Website: www.vumc.org/vecd
The VECD Fogarty Global Health Fellowship is a one-year NIH-funded opportunity for pre- and postdoctoral trainees from Vanderbilt, Emory, Cornell, and Duke Universities and partner institutions interested in working in low-resource settings.
The fellowship is open to:
- Postdoctoral trainees within three years of their last major training (i.e. degree program, residency, fellowship)
- Advanced doctoral students currently enrolled in health-related doctoral programs
Burroughs Wellcome Fund: Investigators in the Pathogenesis of Infectious Disease (PATH), due annually in July
July 16, 2018 : Pre-proposal deadline
by Oct. 1, 2018 : Invitations sent
Nov. 15, 2018 : Full application deadline
The Investigators in the Pathogenesis of Infectious Disease (PATH) award provides $500,000 over five years to support accomplished investigators at the assistant professor level to study pathogenesis, with a focus on the interplay between human and microbial biology, shedding light on how human and microbial systems are affected by their encounters.
Webinars will be held June 14, 18, and 26.
Generating New Insights and Mechanistic Understanding of Antibiotic Resistance Development (R01/R21 Clinical Trial Not Allowed), expires: 05/08/2021
Application Due Date(s): Standard dates apply , by 5:00 PM local time of applicant organization.
The purpose of this Funding Opportunity Announcement (FOA) is to advance select areas of research recognized as critical in the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), including research focused on understanding the nature of microbial communities, how antibiotics affect them, and how they can be harnessed to prevent disease, as well as research exploring combination therapies to address the emergence of resistance.
Ecology and Evolution of Infectious Diseases (EEID), due annually in November
Full Proposal Deadline Date: November 20, 2019
The Ecology and Evolution of Infectious Diseases program supports research on the ecological, evolutionary, and socio-ecological principles and processes that influence the transmission dynamics of infectious diseases. The central theme of submitted projects must be quantitative or computational understanding of pathogen transmission dynamics. The intent is discovery of principles of infectious disease transmission and testing mathematical or computational models that elucidate infectious disease systems. Projects should be broad, interdisciplinary efforts that go beyond the scope of typical studies. They should focus on the determinants and interactions of transmission among humans, non-human animals, and/or plants. This includes, for example, the spread of pathogens; the influence of environmental factors such as climate; the population dynamics and genetics of reservoir species or hosts; the cultural, social, behavioral, and economic dimensions of disease transmission. Research may be on zoonotic, environmentally-borne, vector-borne, or enteric diseases of either terrestrial or freshwater systems and organisms, including diseases of animals and plants, at any scale from specific pathogens to inclusive environmental systems. Proposals for research on disease systems of public health concern to developing countries are strongly encouraged, as are disease systems of concern in agricultural systems. Investigators are encouraged to develop the appropriate multidisciplinary team, including for example, modelers, bioinformaticians, genomics researchers, social scientists, economists, epidemiologists, entomologists, parasitologists, microbiologists, bacteriologists, virologists, pathologists or veterinarians, with the goal of integrating knowledge across disciplines to enhance our ability to predict and control infectious diseases.
https://www.nsf.gov/funding/pgm_summ.jsp?pims_id=5269
Notice of NIH Participation: https://grants.nih.gov/grants/guide/notice-files/NOT-TW-19-007.html
Bloomberg Initiative To Reduce Tobacco Use Grants Program
The Bloomberg Initiative to Reduce Tobacco use Grants Program utilizes World Bank country income groups to establish eligibility to apply for a grant. Organizations from low- and middle-income countries are welcome to apply. This includes low-income, lower-middle-income, and upper-middle-income countries.
Open Grant Round (OGR) – An international competitive grant round, open to applicants from any low or middle-income country. OGR applications should focus on a national policy gap in their country in the PWER areas of MPOWER, or FCTC Article 5.3 policy (this must be in association with strengthening MPOWER policies).
Strategic Grant Round (SGR) – This round is only open to applicants from the ten priority countries, and is focused on the priority issues identified for each of those countries.
The ten priority countries are:
- China
- India
- Indonesia
- Bangladesh
- Pakistan
- Vietnam
- Philippines
- Brazil
- Ukraine
- Mexico
NIMH Exploratory/Developmental Research Grant (R21 Clinical Trial Not Allowed), expires: 01/08/2021
Application Due Date(s): Standard dates apply , by 5:00 PM local time of applicant organization.
The NIMH Exploratory/Developmental Grant program supports exploratory and high-risk research projects that fall within the NIMH mission by providing support for the early and conceptual stages of these projects. These studies may involve considerable risk but may lead to a breakthrough or to the development of novel techniques, agents, methods, measures, models, or strategies, or to the generation of pilot or feasibility data. The preliminary work from these studies could lead to a major impact on biomedical, behavioral, or clinical mental health research, or on the delivery of mental health care.
Congressionally Directed Medical Research Programs (CDMRP), Department of Defense (DOD)
Application Due Date(s): Various times depending on research program.
Synopsis of Current Program Funding Opportunities